Matches in Nanopublications for { ?s ?p "[Epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI) treatment is the standard therapy for non-small cell lung cancer (NSCLC) harbouring EGFR-activating mutations.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en ?g. }
Showing items 1 to 2 of
2
with 100 items per page.
- assertion description "[Epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI) treatment is the standard therapy for non-small cell lung cancer (NSCLC) harbouring EGFR-activating mutations.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- NP1267095.RAtdzcCLIzdpqJEKZfyb9aNiU-xUH3gpXOuxhZxo62Ntk130_assertion description "[Epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI) treatment is the standard therapy for non-small cell lung cancer (NSCLC) harbouring EGFR-activating mutations.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1267095.RAtdzcCLIzdpqJEKZfyb9aNiU-xUH3gpXOuxhZxo62Ntk130_provenance.